Dolovich also identified the use of “omics,” phenotyping, and precision medicine as a trend, along with advances in imaging for improved analysis of deposition and distribution of inhaled drugs in the lung, asking whether there will be an imaging replacement for FEV1.
Delegates look at the DDL 2017 poster exhibition
In his recap of the Wednesday morning pre-conference symposium presented by Siminhale, Wilbur de Kruijf of Medspray summarized a symposium presentation by Wim Vos of FLUIDDA that showed imaging demonstrating the radical respiratory physiology changes seen as a child grows from newborn infant through childhood to adulthood, as well as simulations showing the differences in deposition and distribution for an aerosol delivered via an MDI and spacer across age ranges from newborn to adult.
Sandy Munro of Vectura also described the use of FLUIDDA’s lung deposition modeling using scans of lungs of real patients with idiopathic pulmonary fibrosis (IPF) and employing realistic inhalation maneuvers for selection of a delivery technology that would be most suitable for IPF patients. Munro noted the significant potential for the use of FRI for device selection and optimization or for the evaluation of clinical data, noting the potential use of FRI as a clinical endpoint.
Several presentations discussed other modeling techniques, including a talk by Ulrike Tehler of AstraZeneca, who described development of the company’s Lung-Sim modeling platform, which goes beyond deposition and distribution modeling to predict pharmacokinetic data as an aid in translating between preclinical and clinical studies. Built around the GI-Sim absorption model, the Lung-Sim has successfully used data on deposition, mucociliary clearance, dissolution, and absorption to predict systemic exposure of a drug delivered via inhalation in both animals and humans, she said.
